---
id: varicella-zoster-immunocompromised
condition: Varicella-Zoster Virus Infection in Immunocompromised Patients
aliases: [VZV in immunocompromised, disseminated zoster, shingles immunocompromised, chickenpox immunosuppressed]
icd10: [B02.7, B02.8, B02.9, B01.9]
esi: 2
time_to_harm: "< 48 hours (visceral dissemination); < 72 hours (VZV pneumonitis mortality 10-30%)"
category: infectious
track: tier1
sources:
  - type: guideline
    ref: "NIH Guidelines for Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV: Varicella-Zoster Virus, 2024"
  - type: guideline
    ref: "CDC Clinical Guidance for People at Risk for Severe Varicella, 2024"
  - type: guideline
    ref: "IDSA Clinical Practice Guideline for Management of Varicella-Zoster Virus Infection"
last_updated: "2026-03-01"
compiled_by: agent
risk_tier: A
validation:
  automated_consistency_check: null
  dose_range_validator: null
  unit_normalization_check: null
  cross_file_consistency_check: null
  citation_presence_check: null
  duplicate_content_check: null
  outlier_detection_flag: clear
  schema_version: "2.0"
  provenance_links: []
---
# Varicella-Zoster Virus Infection in Immunocompromised Patients

## Recognition

**Presentation spectrum:**
- **Localized zoster:** Dermatomal vesicular rash on erythematous base (may be atypical — hemorrhagic, necrotic, or non-vesicular in immunocompromised)
- **Disseminated zoster:** > 20 vesicles outside the primary and adjacent dermatomes; generalized vesicular eruption
- **Primary varicella (chickenpox):** Diffuse vesicular rash in crops at different stages
- **Visceral VZV without rash:** Rare but occurs in severely immunocompromised — hepatitis, pneumonitis, encephalitis

**Complications in immunocompromised:**
- VZV pneumonitis (10-30% mortality)
- Hepatitis (fulminant in severe cases)
- Encephalitis, myelitis, vasculopathy (stroke)
- Disseminated intravascular coagulation
- Bacterial superinfection of lesions
- Postherpetic neuralgia (more severe, prolonged)

**High-risk populations:**
- HIV/AIDS (CD4 < 200 cells/mm3)
- Solid organ and hematopoietic stem cell transplant recipients
- Patients on high-dose corticosteroids (> 20 mg prednisone equivalent daily x 14+ days)
- Chemotherapy, biologic agents (anti-TNF, JAK inhibitors)
- Congenital immunodeficiency

## Critical Actions

1. **Acyclovir 10 mg/kg IV q8h** — start immediately for disseminated zoster, visceral involvement, or any VZV in severely immunocompromised
2. **Airborne + contact isolation** — VZV is airborne transmissible from disseminated zoster and primary varicella
3. **Assess for pneumonitis** — CXR, SpO2; VZV pneumonia is the leading cause of mortality
4. **Assess for CNS involvement** — headache, altered mentation, focal deficits warrant LP and MRI
5. **Ophthalmology consultation** if V1 (ophthalmic) dermatome involved — risk of keratitis, uveitis, retinal necrosis

## Differential Diagnosis

- Disseminated HSV — similar vesicular rash; HSV PCR distinguishes
- Disseminated gonococcemia — pustules, tenosynovitis, polyarthralgias
- Drug eruption — temporal relationship to medication, non-vesicular
- Contact dermatitis — pruritic, follows exposure pattern
- Smallpox — synchronous deep-seated lesions (bioterrorism consideration)
- Enteroviral exanthem — nonspecific, mild systemic symptoms
- Bacterial cellulitis — unilateral erythema without vesicles

## Workup

- **VZV PCR** from vesicle fluid or base — gold standard (more sensitive than culture or DFA)
- **Direct fluorescent antibody (DFA)** from lesion scraping — rapid result, moderate sensitivity
- **VZV PCR of blood** — detects viremia in disseminated disease
- **VZV PCR of CSF** — if CNS involvement suspected
- **CBC, BMP, hepatic panel** — baseline organ function
- **CXR** — diffuse nodular/interstitial infiltrates in VZV pneumonitis
- **CT chest** — ground-glass opacities, nodules; more sensitive than CXR
- **MRI brain** if encephalitis suspected
- **LP** if meningitis/encephalitis suspected — lymphocytic pleocytosis, elevated protein
- **Coagulation studies** if disseminated disease (DIC screen)

## Treatment

### IV Antiviral (Disseminated, Visceral, Severe)
- **Acyclovir 10-15 mg/kg IV q8h** (higher dose 15 mg/kg for life-threatening disease)
- Infuse over 1 hour with adequate hydration (prevent crystalline nephropathy)
- **Duration:** Continue IV until no new lesions for 48h AND clinical improvement; minimum 7-10 days IV
- Transition to oral valacyclovir 1000 mg PO TID to complete total 10-14 days (longer for encephalitis: 14-21 days)

### Oral Antiviral (Localized Zoster, Mild Immunosuppression)
- **Valacyclovir 1000 mg PO TID x 7-10 days** (preferred oral agent)
- OR Acyclovir 800 mg PO 5 times/day x 7-10 days
- Initiate within 72 hours of rash onset (ideally within 24h)

### Acyclovir-Resistant VZV
- **Foscarnet 40 mg/kg IV q8h** (or 60 mg/kg q12h)
- Usually occurs in severely immunocompromised after prolonged acyclovir exposure
- Nephrotoxic — aggressive hydration, monitor Ca, Mg, K, PO4
- Infectious disease consultation recommended

### Renal Dosing
- CrCl 25-50 mL/min: Acyclovir 10 mg/kg IV q12h
- CrCl 10-25 mL/min: Acyclovir 10 mg/kg IV q24h
- CrCl < 10 mL/min: Acyclovir 5 mg/kg IV q24h

### Supportive
- Pain management: gabapentin 300-1200 mg PO TID, acetaminophen, opioids PRN for severe pain
- Calamine lotion, cool compresses for pruritus
- Bacterial superinfection: add empiric antibiotics if cellulitis develops

## Disposition

- **Disseminated/visceral VZV:** ICU or monitored bed; IV acyclovir
- **Localized zoster in immunocompromised:** Admit for IV acyclovir if severe immunosuppression (CD4 < 200, active chemo, high-dose steroids); may treat outpatient with close follow-up if mildly immunosuppressed and no visceral involvement
- **Isolation:** Airborne + contact precautions until all lesions crusted (may take 7-10 days in immunocompromised; longer than immunocompetent)
- **Exposed susceptible immunocompromised contacts:** Post-exposure prophylaxis with varicella-zoster immune globulin (VariZIG) 125 IU/10 kg IM (max 625 IU) within 10 days of exposure, or valacyclovir 1000 mg PO TID days 3-22 post-exposure
- **Reportable:** Varicella is reportable in most US states

## Pitfalls

1. **Failing to isolate.** Disseminated VZV and primary varicella are airborne-transmissible. Immunocompromised patients on the same ward can develop fatal primary varicella from exposure. Negative-pressure room required.

2. **Treating disseminated zoster with oral antivirals.** Oral acyclovir has only ~20% bioavailability. Disseminated or visceral VZV in immunocompromised patients requires IV acyclovir.

3. **Missing VZV without rash.** Immunocompromised patients can develop visceral VZV (hepatitis, pneumonitis, encephalitis) without skin lesions. Maintain high index of suspicion in febrile immunocompromised patients with organ dysfunction.

4. **Assuming crusted lesions are non-infectious in immunocompromised.** Immunocompromised patients may have prolonged viral shedding even from crusted lesions. VZV PCR of lesion can confirm ongoing infectivity.

5. **Not consulting ophthalmology for V1 zoster.** Herpes zoster ophthalmicus can cause permanent vision loss from keratitis, uveitis, or acute retinal necrosis. Hutchinson sign (vesicles on nasal tip) indicates nasociliary nerve involvement and high risk of ocular complications.

6. **Failure to provide post-exposure prophylaxis to susceptible immunocompromised contacts.** VariZIG is most effective within 96 hours of exposure but can be given up to 10 days.
